Clinical effects of wasabi extract containing 6-MSITC on myalgic encephalomyelitis/chronic fatigue syndrome: an open-label trial

Table 8 Changes in health-related quality of life after 6-MSITC treatment

	Pre	Post	Δ	P	ES
SF-36
Physical function	30.4 ± 18.2	29.9 ± 16.6	-0.48 ± 8.9	0.838	0.05
Role physical	24.9 ± 13.1	27.8 ± 9.2	2.9 ± 14	0.442	-0.2
Bodily pain	38.2 ± 12.2	41.1 ± 11.8	2.9 ± 10.8	0.319	-0.27
General health perception	33.4 ± 6.2	36.8 ± 8.1	3.4 ± 5.6	0.036	-0.6
Vitality	32.7 ± 7.9	35.7 ± 9.0	2.98 ± 5	0.039	-0.59
Social functioning	33.4 ± 10.5	34.7 ± 13.1	1.27 ± 15.4	0.754	-0.08
Role emotional	41.4 ± 12.5	41.9 ± 14.7	0.56 ± 8.7	0.808	-0.06
Mental health	43.8 ± 9.3	44.1 ± 10.2	0.37 ± 5.2	0.784	-0.07
PCS	30.5 ± 18.4	32.3 ± 13.9	1.87 ± 8.9	0.435	-0.2
MCS	42.9 ± 9.1	45.3 ± 7.8	2.36 ± 4.8	0.08	-0.49
RCS	40.1 ± 12.3	39.9 ± 11.7	-0.2 ± 10.3	0.941	0.02

Δ: differences between scores before and after treatment (subtraction of Pre from Post). ES: effect sizes were calculated using Cohen’s d. P: p values were analyzed using a parametric paired Student’s t-test. SF-36 Short Form Health Survey, PCS Physical component summary, MCS Mental component summary, RCS Role/Social component summary; (n = 15)

ISSN: 1751-0759